Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

Rhea-AI Summary

Akouos, a Boston-based precision genetic medicine company, has announced it will present new nonclinical data at the ARO 45th Annual Mid-Winter Meeting in San Jose, California, from February 5 to 9, 2022. The presentations will focus on AK-antiVEGF, a gene therapy aimed at treating vestibular schwannoma, showcasing Akouos' capabilities in addressing various inner ear conditions. Key presentations on February 6 include topics on drug delivery and gene silencing methods, presented by leading researchers in the field.

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45^th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.

The two podium presentations and one poster will highlight nonclinical data that support future clinical development of AK-antiVEGF, a gene therapy intended for the treatment of vestibular schwannoma, and demonstrate how Akouos could leverage its multimodal genetic medicine capabilities to address a broad range of inner ear conditions. Details are as follows:

Podium Presentation Title: Tailoring Regulatory Elements in Gene Therapies for Hearing Loss
Date/Time: Sunday, February 6, 2022 from 2:45 to 3:00 p.m. PST
Presenting Author: Danielle R. Lenz, Ph.D.
Topic: Inner Ear: Drug Delivery
Podium Session: 11

Podium Presentation Title: Demonstration of Secreted Protein Expression Levels Following Intracochlear Delivery of AK-antiVEGF (AAVAnc80-antiVEGF Vector) Across Multiple Doses in Non-Human Primates
Date/Time: Sunday, February 6, 2022 from 3:00 to 3:15 p.m. PST
Presenting Author: Michelle Valero, Ph.D.
Topic: Inner Ear: Drug Delivery
Podium Session: 11

Poster Presentation Title: In Vitro Characterization of Gene Silencing Methods with the Potential to Treat Autosomal Dominant Hearing Loss
Date/Time: Sunday, February 6, 2022 12:00 p.m. PST to Monday, February 7, 2022 1:00 p.m. PST
Presenting Author: Robert Ng, Ph.D.
Topic: Inner Ear: Drug Delivery
Poster Number: SU128

About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What data will Akouos present at the ARO meeting in February 2022?

Akouos will present nonclinical data supporting the clinical development of AK-antiVEGF, a gene therapy for vestibular schwannoma.

When will Akouos present their findings on AK-antiVEGF?

Presentations on AK-antiVEGF will occur on February 6, 2022, during the ARO meeting.

Who will present the podium presentations for Akouos?

Danielle R. Lenz, Ph.D., and Michelle Valero, Ph.D., will lead the presentations.

What is the focus of Akouos's research presented at the ARO meeting?

The research focuses on gene therapies for hearing loss and drug delivery methods for inner ear conditions.